China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Apple Turns 50: From Garage Startup to AI Crossroads 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
NEW YORK, Nov. 22, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Northern District of California on behalf of investors who purchased Dynavax Technologies Corporation (NASDAQ:DVAX) securities between March 10, 2014 and November 11, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/dynavax-technologies-corporation. There is no cost or obligation to you.
According to the complaint, during the Class Period Dynavax made false and/or misleading statements and/or failed to disclose that: (i) the phase 3 HBV-23 trial for the Company’s lead vaccine product HEPLISAV-B was not designed in accordance with the U.S. Food and Drug Administration’s concerns and issues, as pointed out in a 2013 Complete Response Letter; (ii) Dynavax failed to provide sufficient information to the FDA in its Revised Biologics License Application for the drug; (iii) Dynavax’s resources will not be sufficient for the Company to advance the HEPLISAV-B program on its own; and (iv) as a result of the foregoing, the Company’s financial statements, as well as Defendants’ statements about Dynavax’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
If you suffered a loss in Dynavax you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/dynavax-technologies-corporation.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
